Hiroshi Watanabe Pegcetacoplan, an investigational drug for post-transplant recurrence of C3 glomerulopathy, a condition that affects the kidneys, from Apellis Pharmaceuticals ( NASDAQ: APLS ) led to a rapid reduction in disease activity at week 12 in a phase 2 study. After one year of treatment, of the 11 patients treated with pegcetacoplan, seven (64%) patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. Six (55%) showed zero C3c staining intensity.
And seven patients (64%) showed zero inflammation. The phase 2 NOBLE study enrolled patients with post-transplant recurrence of C3 glomerulopathy or primary immune complex membranoproliferative glomerulonephritis. More on Apellis Pharmaceuticals Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks Apellis Pharmaceuticals, Inc.
2024 Q1 - Results - Earnings Call Presentation Apellis Pharmaceuticals, Inc. (APLS) Q1 2024 Earnings Call Transcript Apellis stock sell-off over Syfovre sales "overdone," says Citi Apellis Pharmaceuticals Q4 2023 Earnings Preview.
